-
Health Care Fraud Costs Everyone
Without a doubt, our nation’s health care system faces an array of challenges related to quality, affordability, and access. Given the breadth of our challenges, it makes the prevalence of fraud, waste, and abuse in our system that much more frustrating and galling. Depending on …
Read More -
New Report Details Potential Medicaid Savings from Using PBM Tools
In addition to offering significant savings for private health insurers, pharmacy benefit management (PBM) tools could save the Federal government and state governments $74.4 billion in Medicaid costs over ten years according to a new report by the Menges Group prepared for the Pharmaceutical Care …
Read More -
Diabetes Patients May See Improved Outcomes with New Weekly Injection
Diabetes is one of the most common chronic diseases of our generation, affecting about 25.8 million Americans and 371 million people worldwide. Type 2 diabetes accounts for between 90 and 95% of all diabetes cases. For international as well as domestic healthcare agencies, designing an …
Read More -
FDA Blocks U.S. Introduction of Generic OxyContin
This past December, Canada’s Health Ministry approved the manufacture and sale of generic oxycodone in its originally patented non-abuse resistant formulation. This year, it was the FDA’s turn to consider the issue, with Purdue Pharma’s original non-abuse resistant formulation patent of OxyContin expiring April 16th. …
Read More -
Ignore the Fine Print, Just Sign Here Please…
Every so often, we come across an innocuous news article that highlights a divergence between Washington lobbying rhetoric and marketplace practices. Recently, the Wall Street Journal ran a front-page article about Procter & Gamble moving to extend its payment terms with suppliers from an average …
Read More -
Pharmaceutical Companies Playing on Safety Rules to Impede Cost-Saving Generics
In a recent post, we talked about how pharmaceutical companies use “evergreen” techniques to work around the expiration of patents and extend profitable exclusivity periods for branded drugs. Now the New York Times has revealed another set of techniques in what pharmaceutical companies euphemistically call …
Read More -
New Developments on Improving Health and Reducing Costs through Vaccines
As the Affordable Care Act celebrates its third anniversary, the Department of Health and Human Services (HHS) has announced the extension of preventive services coverage to approximately 105 million Americans, including 34 million Medicare beneficiaries. Currently, the U. S. spends close to 18% of the …
Read More -
Changing Behavior through Electronic Prescribing
One of the greatest challenges facing the health care system is how best to influence and change both individuals’ and clinicians’ behaviors. Over the past 50 years, whole industries have sprouted up around exercise, nutrition, obesity control, and smoking-cessation programs. Despite notable set-backs — especially …
Read More -
India’s Supreme Court rules against Novartis in Gleevec case
India, one of the world’s largest manufacturers and exporters of generic drugs, ensured the continued production of generic Gleevec® (imatinib mesylate) in the country with a Supreme Court ruling earlier this month. On April 1, the Indian Supreme Court denied a request for patent protection …
Read More -
Forcing Seniors & Disabled People to Pay Higher Prescription Drug Costs
Every once in a while, independent drugstores push a policy argument that leaves us scratching our heads. The NCPA’s latest notion is the idea that Medicare Part D preferred pharmacy networks might threaten access to quality care and threaten the survival of community pharmacies. In …
Read More
